Back to Search Start Over

Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.

Authors :
Danese E
Raimondi S
Montagnana M
Tagetti A
Langaee T
Borgiani P
Ciccacci C
Carcas AJ
Borobia AM
Tong HY
Dávila-Fajardo C
Rodrigues Botton M
Bourgeois S
Deloukas P
Caldwell MD
Burmester JK
Berg RL
Cavallari LH
Drozda K
Huang M
Zhao LZ
Cen HJ
Gonzalez-Conejero R
Roldan V
Nakamura Y
Mushiroda T
Gong IY
Kim RB
Hirai K
Itoh K
Isaza C
Beltrán L
Jiménez-Varo E
Cañadas-Garre M
Giontella A
Kringen MK
Haug KBF
Gwak HS
Lee KE
Minuz P
Lee MTM
Lubitz SA
Scott S
Mazzaccara C
Sacchetti L
Genç E
Özer M
Pathare A
Krishnamoorthy R
Paldi A
Siguret V
Loriot MA
Kutala VK
Suarez-Kurtz G
Perini J
Denny JC
Ramirez AH
Mittal B
Rathore SS
Sagreiya H
Altman R
Shahin MHA
Khalifa SI
Limdi NA
Rivers C
Shendre A
Dillon C
Suriapranata IM
Zhou HH
Tan SL
Tatarunas V
Lesauskaite V
Zhang Y
Maitland-van der Zee AH
Verhoef TI
de Boer A
Taljaard M
Zambon CF
Pengo V
Zhang JE
Pirmohamed M
Johnson JA
Fava C
Source :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Jun; Vol. 105 (6), pp. 1477-1491. Date of Electronic Publication: 2019 Feb 17.
Publication Year :
2019

Abstract

The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was to undertake a meta-analysis at the individual patients level to capture the possible effect of ethnicity, gene-gene interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the authors of our previous meta-analysis (30 articles) and of 38 new articles retrieved by a systematic review to send us individual patients' data. The final collection consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7-10%), with a higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful for clinical practice were derived.<br /> (© 2018 The Authors Clinical Pharmacology & Therapeutics © 2018 American Society for Clinical Pharmacology and Therapeutics.)

Details

Language :
English
ISSN :
1532-6535
Volume :
105
Issue :
6
Database :
MEDLINE
Journal :
Clinical pharmacology and therapeutics
Publication Type :
Academic Journal
Accession number :
30506689
Full Text :
https://doi.org/10.1002/cpt.1323